Geref (sermorelin acetate for injection)

Serono Laboratories

Approval Status
Approved October 1997

Treatment for
pediatric growth disorders

Diabetes / Endocrinology , Pediatrics

Serono Laboratories announced that Geref (sermorelin acetate for injection), its growth hormone releasing hormone, has received marketing clearance from the U.S. Food and Drug Administration. (FDA). Geref is indicated for growth hormone deficiency in children with growth failure and offers a new alternative of treatment.

Geref (sermorelin acetate for injection) Drug Information

The Geref (sermorelin acetate for injection) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top